

QUERCEFIT®

QUERCETIN PHYTOSOME®



Please note this documentation is available for various countries all over the world and hence it may contain statements or product classification not applicable to your country. The claims made are in reference to ingredients only, hence they do not refer to finished products and they may not comply with Regulation EC n. 1924/2006. The marketer of any finished product containing any ingredient is responsible for assuring that the destination of the product and the claims made for the finished product are lawful and comply with all applicable laws and regulations of the country or countries in which the product is to be sold.

WHAT IS QUERCEFIT®?

QUERCEFIT® is the patent pending¹ food grade delivery system of quercetin from Sophora japonica L., formulated with Phytosome® proprietary technology to optimize the biological absorption of the flavonoids, supporting the overall wellbeing in many conditions. Compared to the unformulated quercetin, bioabsorption and solubility are greatly optimized so it can be used at lower dosages retaining its efficacy.²

IMMUNITY HEALTH, SENOLYTIC FUNCTION AND COVID-19

Human studies^{3,4} show that **QUERCEFIT®** helps maintaining immune system health and modulates cytochines cascade, thus **improving the conditions of those exposed** to Covid-19, precisely thanks to its senolytic function: the product supplementation helps the health condition of people in the initial phases of SARS-CoV-2, without substituting the standard treatments envisaged by the medical protocols. In fact, the severity of illness often depends by the way the initial phases are faced. A recent human study⁵ involving 120 high exposure healthcare workers show that **QUERCEFIT®** supplementation helps maintaining health conditions in 75% people working in a COVID-19 infectious environment.

Such evidences confirm once more the efficacy of quercetin, formulated with Phytosome® delivery system, in being a favourable supplementation in situations where possible exposition to SARS-CoV-2 risks is higher.

THE NATURAL REMEDY IN THE ALLERGY ERA

In a first controlled human study on discomforts during allergy season, after 30 days of supplementation with QUERCEFIT® plus the standard management (SM) versus the SM alone, it has been demonstrated:

- up to 50% reduction of day intermittent discomforts frequency
- up to 70% reduction of night intermittent discomforts frequency
- maintenance of breath function (Peak Expiratory Flow) at physiological levels in mild-persistent discomforts

In a second controlled **human study** focussing **on local skin discomforts**, **QUERCEFIT®** was **administrated for just 3 days**, then followed by a local histamine skin stimulus.

Compared to the control, only the **healthy volounteers administered with the extract** showed statistically significant:⁷

- dose-dependent control of all main local conditions;
- skin conditions amelioration and capillary filtration reduction

S P E C I F I C A T I O N S

- 34-42% quercetin by HPLC suggested dose: 250 mg once or twice a day
- yellow powder for use in nutritional supplements
- compliant with main worldwide markets food regulations (BELFRIT, US, EU)
- high tolerability when assuming antiplatelet agents, anticoagulants or living with diabetes.

BETTER PERFORMANCE, FASTER RECOVERY

In a controlled human study on healthy triathlon athletes, QUERCEFIT demonstrated to support optimal physical performance and prompt recovery:

- statistically significant **results in each single triathlon test** (swimming, biking, running);
- higher triathlon time reduction (-11.3%) compared to control (-3.9%) after just 14 days of oral supplementation;
- reduced discomfort related to sport activity;
- lower oxidative stress (PFR) 1 hr after the final run
 (Higher levels of PFR found in control have been associated to a delayed recovery time from fatigue);
- healthy blood levels maintenance, with a reduced UBR (Unconjugated Bilirubin) and LDH (Lactate Dehydrogenase), after prolonged sport activity.

References

- ¹ International patent application number PCT EP2018/054533 filed on 23/02/2018
- ² Riva A. et al., Eur J Drug Metab Pharmacokinet. 2018 Oct 16. doi: 10.1007/s13318-018-0517-3
- Di Pierro et al., International Journal of General Medicine 2021:14 2359-2366
- ⁴ Di Pierro *et al.*, International Journal of General Medicine 2021:14 2807–2816.
- ⁵ Rondanelli, M. *et al*. Life 12.1 (2022): 66.
- ⁶ Cesarone, M. R., et al., Minerva medica (2019).
- ⁷ Riva A. et al., Minerva Cardioangiol. 2018 Sep 13. doi: 10.23736/S0026-4725.18.04795-3.
- 8 Manuscrit submitted
- 9 Riva A. et al., Minerva Medica 2018 august;109(4):285-9.





HEADQUARTERS - INDENA S.p.A.

Viale Ortles, 12 20139 Milan - Italy tel. +39 02 574961

INDENA BIOTECHNOLOGY (Shanghai) Co., Ltd.

Unit 810, Plaza 336, No.336 Middle XiZang Road Shanghai 200001- China tel. +86 21 2281 5900

INDENA Brasil Ltda

Rua Bandeira Paulista, 600 CEP 04532-001 São Paulo - Brazil tel. +55 1 127 690 624

INDENA JAPAN Co., Ltd.

KDDI Bld. 21F. 1-8-1 Otemachi Chyoda-Ku Tokyo 100-0004 - Japan tel. +81 3 3243 9924

INDENA S.A.S.

7, Rue Lamennais 75008 Paris - France tel. +33 1 45229128

INDENA USA Inc.

Two Union Square 601 Union Street, Suite 330 Seattle, WA 98101 - USA tel. +1 206 340 6140

indena.com







